[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 278
Citations 0
Comment & Response
Less Is More
October 2015

Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness

Author Affiliations
  • 1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam
  • 2Department of Public Health, Erasmus University Medical Center, Rotterdam
  • 3Department of Epidemiology, Erasmus University Medical Center, Rotterdam
  • 4Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam
JAMA Intern Med. 2015;175(10):1724-1725. doi:10.1001/jamainternmed.2015.3997

To the Editor We read with great interest the article by Kutner et al.1 The authors showed that discontinuing statins in patients with a limited life expectancy is safe and may lead to improved quality of life. The accompanied editorial2 states that the statin trial provides a starting point for deprescribing trials in frail patients with advanced illness.

First Page Preview View Large
First page PDF preview
First page PDF preview